<DOC>
	<DOCNO>NCT02710890</DOCNO>
	<brief_summary>EP0060 multicenter , open-label study evaluate safety tolerability intravenous ( iv ) Lacosamide ( LCM ) pediatric subject &gt; = 4 &lt; 17 year age epilepsy .</brief_summary>
	<brief_title>Study Investigate Safety Tolerability Intravenous Lacosamide Children .</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Male female &gt; =4 &lt; 17 year age Subject diagnosis epilepsy partialonset seizure primary generalize tonicclonic seizure Subject meet 1 follow criterion : 1 . Openlabel lacosmide ( OLL ) subject : Subject currently receive oral lacosmide ( LCM ) adjunctive monotherapy participant open label longterm study ( SP848 , EP0034 , pediatric study ) ; OR , 2 . Prescription lacosamide ( RxL ) subject : Subject currently receive prescribe oral LCM commercial supply ( eg , VIMPAT ) adjunctive monotherapy ; OR , 3 . Initiating intravenous lacosamide ( IIL ) subject : Subject currently receive LCM receive intravenous ( iv ) LCM adjunctive treatment EP0060 . Initiation LCM monotherapy permit IIL subject . Subject OLL RxL subject meet follow criterion : 1 . Subject administer LCM treatment epilepsy least 2 week prior Screening ; AND , 2 . Subject administer ( OLL ) prescribe ( RxL ) oral LCM dose 2mg/kg/day 12mg/kg/day ( subject &lt; 50kg ) 100mg/day 600mg/day ( subject &gt; =50kg ) . Openlabel study drug LCM ( OLL ) prescribe oral LCM dose ( RxL ) must stable least 3 day prior first LCM infusion ; OR , Subject ILL subject stable dosage regimen least 1 antiepileptic drug ( AED ) . The daily dosage regimen concomitant AED therapy must keep constant period least 2 week prior Screening . Subject acceptable candidate venipuncture iv infusion Subject , opinion investigator , able comply study requirement . Subject ( parent [ ] legal representative ) willing comply study requirement Subject previously receive intravenous ( iv ) lacosamide ( LCM ) study Subject medical , neurological , psychiatric condition , opinion investigator , could jeopardize subject 's health compromise subject 's ability participate EP0060 Subject clinically significant hypotension bradycardia opinion investigator Subject &gt; =6 year age lifetime history suicide attempt ( include actual attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either Question 4 Question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening For openlabel lacosamide ( OLL ) subject , enrollment EP0060 permit follow additional criterion meet : Subject ongoing Adverse Event ( AE ) longterm , openlabel study , opinion investigator , could jeopardize would compromise subject 's ability participate EP0060 subject meet criteria require withdrawal longterm openlabel study For prescription lacosamide ( RxL ) initiate intravenous lacosamide ( IIL ) subject , enrollment EP0060 permit follow additional criterion meet : Subject medical condition could reasonably expect interfere drug absorption distribution , metabolism , excretion Subject female childbearing potential practice acceptable method contraception duration participation EP0060 Subject creatinine clearance le 30 mL/min Subject clinically relevant electrocardiogram ( ECG ) abnormality , opinion principal investigator ( ie , second third degree heart block rest QT prolongation great 450ms ) Subject hemodynamically significant heart disease ( eg , heart failure ) Subject arrhythmic heart condition require medical therapy , know cardiac sodium channelopathy , Brugada syndrome Subject know history severe anaphylactic reaction serious blood dyscrasia Subject acute subacutely progressive central nervous system disease . Subject epilepsy secondary progress cerebral disease progressive neurodegenerative disease ( malignant brain tumor Rasmussen syndrome ) Lacosamide intend treatment generalize convulsive status epilepticus Subject diagnosis Dravet 's syndrome For IIL subject , enrollment EP0060 permit follow additional criterion meet : Subject treat LCM within last 3 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>pediatric</keyword>
	<keyword>intravenous</keyword>
	<keyword>child</keyword>
	<keyword>Lacosamide</keyword>
	<keyword>VIMPATÂ®</keyword>
	<keyword>seizure</keyword>
</DOC>